GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avidity Biosciences Inc (NAS:RNA) » Definitions » 5-Year EBITDA Growth Rate

RNA (Avidity Biosciences) 5-Year EBITDA Growth Rate : -49.10% (As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Avidity Biosciences 5-Year EBITDA Growth Rate?

Avidity Biosciences's EBITDA per Share for the three months ended in Sep. 2024 was $-0.79.

During the past 3 years, the average EBITDA Per Share Growth Rate was -16.50% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was -49.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 6 years, the highest 3-Year average EBITDA Per Share Growth Rate of Avidity Biosciences was -16.50% per year. The lowest was -79.60% per year. And the median was -60.60% per year.

Competitive Comparison of Avidity Biosciences's 5-Year EBITDA Growth Rate

For the Biotechnology subindustry, Avidity Biosciences's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Avidity Biosciences's 5-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avidity Biosciences's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Avidity Biosciences's 5-Year EBITDA Growth Rate falls into.


Avidity Biosciences 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Avidity Biosciences  (NAS:RNA) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Avidity Biosciences 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Avidity Biosciences's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Avidity Biosciences Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avidity Biosciences Inc (NAS:RNA) » Definitions » 5-Year EBITDA Growth Rate
Comparable Companies
IMNM MRNS CGEM CDMO GHRS GNLX ORTX OCS BMEA RAPT OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
10578 Science Center Drive, Suite 125, San Diego, CA, USA, 92121
Website
https://www.aviditybiosciences.com
Avidity Biosciences Inc is a biotechnology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Its product, AOC 1001, is designed to treat a rare monogenic muscle disease.
Executives
Arthur A Levin officer: Chief Scientific Officer 1896 RUTHERFORD ROAD, CARLSBAD CA 92008
Teresa Mccarthy officer: Chief Human Resources Officer 10975 N TORREY PINES RD #150, LA JOLLA CA 92037
Michael F Maclean officer: Chief Financial Officer 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Tamar Thompson director C/O AVIDITY BIOSCIENCES, INC., 10975 N. TORREY PINES RD., SUITE 150, LA JOLLA CA 92037
W. Michael Flanagan officer: Chief Technical Officer C/O AVIDITY BIOSCIENCES, INC., 10975 N. TORREY PINES RD., SUITE 150, LA JOLLA CA 92037
Sarah Boyce director, officer: President and CEO C/O IONIS PHARMACEUTICALS, INC., 2855 GAZELLE COURT, CARLSBAD CA 92010
Eric Mosbrooker director C/O HORIZON PHARMA, PLC, ADELAIDE CHAMBERS, PETER STREET, DUBLIN 8 L2 000000
Rtw Investments, Lp 10 percent owner 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Jean Jinsun Kim director C/O AVIDITY BIOSCIENCES, INC., 10975 N. TORREY PINES RD., SUITE 150, LA JOLLA CA 92037
Jae B. Kim officer: Chief Medical Officer C/O AVIDITY BIOSCIENCES, INC., 10975 N. TORREY PINES RD., SUITE 150, LA JOLLA CA 92037
Cormorant Asset Management, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Kaye Edward M. Md director 3450 MONTE VILLA PARKWAY, BOTHELL WA 98011
Cormorant Global Healthcare Master Fund, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Bihua Chen director, 10 percent owner C/O CORMORANT ASSET MANAGEMENT, LP, 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Roderick Wong director, 10 percent owner C/O RTW INVESTMENTS, LP, 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014